Carfilzomib (K) Plus Lenalidomide (R) and Dexamethasone (D) for BTK Inhibitors Relapsed-refractory or Intolerant Mantle Cell Lymphomas: a Phase II Study
Latest Information Update: 22 May 2023
At a glance
- Drugs Carfilzomib (Primary) ; Dexamethasone (Primary) ; Dexamethasone (Primary) ; Lenalidomide (Primary) ; Lenalidomide (Primary)
- Indications Mantle-cell lymphoma
- Focus Therapeutic Use
- Acronyms FIL_KLIMT
Most Recent Events
- 14 Sep 2022 Planned End Date changed from 30 Sep 2022 to 8 Dec 2022.
- 17 Dec 2021 Planned End Date changed from 30 Apr 2022 to 30 Sep 2022.
- 19 Apr 2021 Status changed from recruiting to active, no longer recruiting.